Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

August 3, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 59 min

Earnings Call Speaker Segments

Larry Keusch

executive
#1

Good morning, everyone, and thank you for being with us on this call about Teleflex Incorporated's second quarter 2023 earnings. Our website, teleflex.com, has both the press release and the slides for today. If you're viewing the webcast, you're able to advance the slides yourself, so please keep pace with us as the presentation proceeds. Also note that a replay will be made available on our site, and the details for accessing it appear in the press release we issued this morning. Joining us today are Liam Kelly, our Chairman, President and Chief Executive Officer, along with Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom are going to deliver their prepared comments, and once they're done, we'll take questions from the audience. Ahead of getting started, a quick reminder: certain topics we'll cover on this conference call will include forward-looking statements about future events, as described in the slides available in the Investor Relations portion of the Teleflex website. Please be aware that these statements are indeed forward-looking by nature, and they carry risks and uncertainties, so actual events or results could turn out materially different. Several elements might lead real outcomes or occurrences to diverge substantially from expectations. These encompass, though they aren't restricted to, the items mentioned in the press release we issued earlier today, along with the documents we submit to the SEC — among them our Form 10-K — all of which are available through our site. At this point, I'll hand things over to Liam so he can share his comments.

Liam Kelly

executive
#2

I appreciate that, Larry, and hello everybody on this morning's call. It's great to be here with all of you today. During today's session, we'll go over the results for the second quarter of 2023, the acquisition of Palette Life Sciences that is still pending, and the financial guidance we're providing for 2023. Now, shifting to Q2, Teleflex posted revenues of $743.3 million, which marks a 5.5% rise versus the prior year on a reported basis, and a 5.9% rise on a constant currency basis. Adjusted earnings per share for the second quarter came in at $3.41, up 0.6% compared with the same period a year earlier. Utilization stayed steady across the acute care setting in the global markets we serve. The balanced results this quarter once again show what Teleflex gains from having a diversified product portfolio and a wide geographic footprint. Looking at the macro picture, we keep observing sequential stabilization when it comes to material inflation, and we'll keep watching trends through the back half of 2023. Our supply chain held steady during the second quarter, though we have not yet returned to normal levels. As we had anticipated, we continued to see hospital staffing stabilize. That showed up in our Q2 revenue growth, since the majority of Teleflex products are tied to the hospital setting. Conversely, staffing challenges remain more persistent in certain regions on the ASC and office sides of the business, although we're seeing some relief from those constraints. Now, let's examine how revenue performed during Q2. First, I'll walk through the geographic segment results for the quarter. Unless I note otherwise, all growth figures I cite are calculated on a constant currency basis. In the Americas, revenue totaled $424.7 million, which represents 3% growth compared with the same period last year. In particular, our Vascular, Interventional and Surgical businesses turned in strong results. EMEA revenue was $147.8 million, up 0.7% year over year. During the quarter, our vascular and urology drainage businesses showed notable strength. Turning to Asia now. That region brought in $86.7 million, which is 19.1% higher than the same period a year ago. Throughout Q2, demand held steady across the region, and China in particular grew by more than 20%. Breaking it down by product, both Interventional Access and Interventional Urology posted solid double-digit gains regionwide. Now let's turn to second quarter revenues broken out by global product categories. As with the earlier figures, any discussion of global product category growth for Q2 will be given on a constant currency basis. Starting with Vascular Access: revenue climbed 6.6%, reaching $173.8 million, reflecting solid execution on our part during the second quarter. Early launch efforts for the next-generation Arrow VPS Rhythm DLX navigation device, along with the new Arrow PICC pre-loaded with the NaviCurve Stylet, have drawn a favorable response from customers. Looking ahead, we believe we're set up for reliable growth over the long haul, thanks to our leadership position in Central Venous Catheters and midlines, along with expected share gains from our innovative coated PICC lineup and upcoming product launches. Shifting to Interventional Access, revenue reached $124.8 million, which represents a 9.6% increase over the same period last year. Procedure volumes held steady during the quarter, and our diversified portfolio keeps working in our favor. Double-digit growth was recorded across balloon pumps, right heart catheters, and access and closure products. MANTA is still expected to achieve strong double-digit growth in 2023. Turning now to Anesthesia, revenue totaled $100.8 million, down 3.6% compared with the prior-year period. The quarter's performance took a hit because the prior-year period included military orders whose timing made for a tough comparison. Revenue in our Surgical segment came in at $106 million, up 7.7% from the same quarter a year ago. As we worked through the period, we kept advancing the integration of Standard Bariatrics, and there's growing momentum behind training additional surgeons on the Titan SGS Stapler for sleeve gastrorectomy procedures. Turning to Interventional Urology, revenue was $77.8 million, a decline of 2.3% versus last year's comparable period. Once more, UroLift posted year-over-year growth in the hospital channel, even as the office portion of the business keeps encountering headwinds. Our international launch activities remain on track as planned, and UroLift utilization in Japan is climbing at the rate we anticipated. OEM revenues climbed 19.8% from a year ago to $84.1 million. The quarter's strength was widespread across our portfolio, with every one of our product categories achieving double-digit growth, micro catheters included. We still enjoy solid visibility into the business and observe healthy demand trends across 2023. Other revenue for the second quarter rose 4.8%, reaching $76 million versus the prior-year period. Our expectation remains that all MSA revenues will end once 2023 concludes. That wraps up my remarks on second quarter revenue performance. Shifting to a few commercial updates. Back on July 26, we announced a finalized deal to acquire Palette Life Sciences, which is privately held. The structure includes $600 million in cash paid upfront when the transaction closes, along with up to $50 million more contingent on achieving specific commercial milestones. Through this purchase, Teleflex Interventional Urology will expand to include a lineup of NASHA — that's Non-Animal Stabilized Hyaluronic Acid — spacer and tissue bulking offerings that are growing quickly and improve results for patients across urology, urogynecological disorders, colorectal issues, and radiation oncology procedures. For fiscal year 2023, Palette is expected to generate approximately $56 million in net sales on a stand-alone basis. Looking ahead, we expect Palette to contribute significantly to our growth in the years to come, with revenue climbing somewhere between the high teens and low 20% range compared to the prior year in 2024. The strength of Palette's growth trajectory gives us greater confidence that we will achieve the LRP growth targets we've set for 2023 through 2025. Palette's flagship offering is the Barrigel rectal spacer, which generates the majority of the company's revenue. As a NASHA spacer, Barrigel delivers a strong value proposition: it reduces the amount of radiation reaching the rectum during prostate cancer radiation therapy, while also improving tumor control and patients' quality of life. In addition, the Palette Life Sciences portfolio includes Deflux and Solesta, both NASHA-based tissue bulking agents, designed respectively to treat pediatric vesicoureteral reflux and fecal incontinence. Bringing Palette Life Sciences on board lets us fold this thrilling, fast-expanding, high-margin technology into our Interventional Urology business units, alongside the well-established global call points we already have; our aim is delivering urologists and other specialists more cutting-edge technologies capable of positively affecting patient care. Three main reasons make the Palette deal appealing. To start, Barrigel stands out as a differentiated rectal spacer boasting a robust growth trajectory since receiving FDA clearance in May of 2022, and it serves as an extremely complementary offering to the Interventional Urology business we already run; over recent years, prostate cancer treatment has leaned more and more on hypofractionated radiation therapy, delivering larger radiation doses across fewer sessions. To cut down on complications tied to radiation, the use of temporary rectal spacers has risen as a means of shielding healthy rectal tissue from damaging radiation. Barrigel's growth has come through widening market adoption since launch, thanks to its distinctive product characteristics. Differing from competing technologies, Barrigel can be easily sculpted once positioned between the prostates and rectum, delivering thorough protection against radiation therapy. This moldability lets the physician secure predictable safeguarding of healthy rectal tissue ahead of radiation therapy. Barrigel additionally shows up clearly on transrectal ultrasound, helping ensure accurate placement, is biodegradable, and provides an one-step assembly of the delivery device across all sites of service. Next, a sizable and expanding worldwide market exists for rectal spacers.

Liam Kelly

executive
#3

According to projections from the American Cancer Society, 288,000 fresh prostate cancer diagnoses are expected in the U.S., and incidence is rising at 3% annually. On top of that, growing adoption of hypofractionated radiation therapy is fueling need for rectal spacers that shield healthy tissue. Barrigel received marketing clearance in the United States and Australia, and it holds a CE Mark. Over the next several years, we anticipate securing market clearances in further geographies. Third, buying Palette demonstrates how disciplined we are when deploying capital. Strategically speaking, adding Palette's NASHA portfolio dovetails with the robust position we hold in treating benign prostate enlargement. Notably, the bulk of rectal space replacements are carried out by urologists, so our large, well-established sales force will be leveraged. As of today, 97% of physicians who use UroLift also manage prostate cancer. Moreover, prostate cancer treatment cannot be postponed, meaning we are bringing in one more durable growth driver for our portfolio. We likewise anticipate that interest in rectal spacers will open doors for cross-selling UroLift. Financially, this deal aligns with our approach of acquiring assets that boost Teleflex's growth rate and margins. Palette's adjusted gross margin will lift both the corporate average and the Interventional Urology business unit. Beyond that, we anticipate Palette's operating margin will improve the corporate average in the near term. Last, once the transaction closes, our balance sheet stays healthy, which lets us keep carrying out our long-term capital deployment strategy. Completion depends on customary closing conditions, among them receipt of certain regulatory approvals, and the deal should close in the fourth quarter of 2023. We are eager to welcome Palette's employees into Teleflex. Now to an update regarding the Titan SGS stapler. We keep advancing our commercial strategy for the Titan SGS power stapling device, which is used in sleeve gastrorectomy procedures to treat obesity. Responses to the Titan stapler continue to be favorable, and our confidence in the Titan SGS stapler's value proposition is unchanged. Its 23-centimeter continuous staple line allows for optimal pouch creation and eliminates the overlapping staples often seen with traditional powered staplers. We are hopeful that, over time, we can produce data demonstrating fewer complications and significant time savings for each procedure. Even with ongoing favorable feedback from the field, we now anticipate Titan stapler revenues landing in the high-teens for 2023, below what had been assumed in our initial guidance for 2023. Value Analysis Committee clearance has moved more slowly than expected, which has held back our capacity to train surgeons. We have taken lessons from that early experience and have sharpened our tactics for obtaining VAC approval. Those efforts are gaining traction, with over 2x as many surgeons trained in the second quarter of 2023 compared with the first quarter of the year. Beyond that, a robust group of surgeons is lined up awaiting proctoring, so we anticipate additional gains as the year progresses, and we keep tracking how GLP-1 medications are used for obesity treatment. According to what our market checks show, our impression is that GLP-1s did affect bariatric surgery volumes somewhat during the second quarter; because of unresolved questions regarding reimbursement and the safety profile, judging the market's long-term impact is still premature. Meanwhile, our sharpest attention stays on capturing share in a sizable sleeve gasterectomy market exceeding 120,000 procedures across the United States, since the Titan stapler launch is at quite an early stage. Our confidence remains that throughout the LRP period the Titan stapler will contribute meaningfully to our high-growth portfolio. That wraps up what I had prepared to say. At this point, I'd like to hand the call to Tom so he can walk through our second quarter financial results in greater detail. Tom?

Tom Powell

executive
#4

Thank you, Liam, and good morning to everyone. Keeping in mind what was discussed earlier regarding how the company's revenue performed, I'd like to begin by addressing margins. For the quarter, adjusted gross margin landed at 59%, reflecting a decline of 60 basis points relative to the equivalent period last year. Several factors drove that year-over-year decrease, chiefly persistent cost inflation, product recalls, and an adverse productivity effect tied to raw material supply — though these were partially countered by favorable price, lower costs related to logistics and distribution, and benefits from cost improvement initiatives. Turning now to price, our outlook remains the same: for 2023, we continue to anticipate positive price of at least 50 basis points on a year-over-year basis. Adjusted operating margin for the second quarter came in at 26.6%. The 90 basis point drop compared with a year earlier was driven by gross margin flow-through, increased employee-related costs and headcount, spending aimed at business expansion, and Standard Bariatrics being included. In the second quarter, net interest expense reached $16.6 million, compared with $11.2 million during the same period last year. The increase in net interest expense relative to the prior year is attributable to interest rates being higher than a year ago, partially offset by lower average debt outstanding. For the second quarter of 2023, our adjusted tax rate was 10.8%, compared with 12% during the equivalent period a year earlier. The decline in our adjusted tax rate from the prior year is mainly the result of lower tax costs tied to U.S. tax law that mandates capitalization of R&D effect. To wrap up on the bottom line: adjusted earnings per share in the second quarter came in at $3.41, which is up 0.6% from the same time last year. Let's shift now to a few balance sheet and cash flow items. Over the first 6 months, operations generated $170.6 million in cash flow, versus $101.9 million during the equivalent period a year earlier. The main drivers behind that gain were reduced tax outlays and beneficial working capital movements. On the balance sheet side, our financial standing keeps giving us the room to run the business and carry out our disciplined approach to allocating capital. When the second quarter closed, cash on hand totaled $250.8 million, down from $292 million at the close of 2022. When it comes to why our cash position went down, the main driver was $154.5 million in payments toward our senior credit facility. That was partly offset by free cash flow of $131.2 million that we brought in over the first 6 months of 2023. At the close of the quarter, net leverage stood at roughly 1.6x, still comfortably under the 4.5x covenant. Now let's move to financial guidance. I'll begin with the Palette Life Sciences acquisition. As we've said before, Palette Life Sciences should deliver net sales of about $56 million in 2023. If we assume the deal closes on December 1, 2023, it isn't expected to have a meaningful effect on Teleflex's 2023 revenue. Looking ahead to 2024, we anticipate this business will post year-over-year revenue growth in the high-teens, below 20% range. If we take the close on December 1, 2023 as our assumption, this deal should add about $0.15 to the company's adjusted EPS for 2023 and roughly $0.35 on a diluted basis for 2024. Then, beginning in fiscal 2025 and continuing annually thereafter, Teleflex expects the acquisition to produce increasing accretion to adjusted earnings per share. The funding for this transaction will come from borrowings under Teleflex's revolving credit facilities plus cash the company already holds. At the time of signing, our balance sheet remained solid, with pro forma net leverage of about 2.5x. That keeps our previously communicated long-term capital deployment approach fully intact. Let me now turn to our 2023 outlook. Based on what we achieved operationally during Q2 and our outlook for the remainder of the year, we're revising our 2023 financial guidance. To be specific, the bottom end of our 2023 constant currency revenue guidance is going up by 50 basis points, which puts the range at 5.5% to 6.25%. Turning to foreign exchange: we now expect translation to contribute roughly $8 million, equal to 30 basis points, of positive impact on GAAP growth for 2023. That's a shift from what we previously told you, when we had anticipated a $10 million negative effect, or 35 basis points, for 2023. Before we go further, note that Q2 top-line figures benefited from currency movements that landed about $6 million above our earlier projection. As for the rest of the revised 2023 effect tied to shifting foreign exchange rates, that ought to unfold across the back half of this year. Our updated outlook on foreign exchange for 2023 folds in the rates we actually saw during Q2, and from here it takes present currency levels as a given — among them a euro-to-dollar rate of $1.10 for the latter six months. When we factor in the updated pressure from foreign exchange, our projection for reported revenue growth in 2023 lands between 5.8% and 6.55%. In dollar terms, that means somewhere from $2.953 billion to $2.974 billion, which works out to a $32 million bump at the bottom of that range and $80 million at the top. Our expectations for gross margin and operating margin in 2023 remain exactly as they were. Moving further down, net interest expense for 2023 is now anticipated to come in around $77 million, driven by additional net borrowings through our revolver tied to the Palette acquisition. As for adjusted earnings per share, we're holding steady on our 2023 guidance of $13 to $13.60. We've revised our adjusted EPS guidance to factor in $0.15 of dilution stemming from the Palette acquisition, plus $0.15 of dilution tied to the ET Tubes and Endurance catheter recall in Q2, which was offset by a $0.15 tailwind from foreign exchange, with the remainder driven by stronger operating results — including second-quarter performance that beat expectations and anticipated stronger growth across the back half of the year. That concludes my prepared remarks, and I'll now turn things back over to Liam for his closing commentary.

Liam Kelly

executive
#5

Thanks, Tom. To wrap up, I want to emphasize 3 main points from Q2 of 2023. To start, durable growth during the second quarter came from our diversified portfolio and global footprint. Execution is still solid; new products are being launched, and our margins are staying healthy. Next, that strong performance in the second quarter leaves us in a good position to meet our financial guidance for 2023. Looking ahead to the latter half of 2023, we expect macro conditions that are stable to improving. Finally, our strategy to drive durable growth will remain a priority. We'll put money into organic growth opportunities and push innovation, widen our margins, and carry out our disciplined capital allocation strategy so that long-term value creation is enhanced. The acquisition of Palette Life Sciences is something we're excited about; in the years ahead, we think this deal will contribute meaningfully to our growth, be immediately accretive to gross margins, and boost our adjusted operating margins in the near term; because of that, we have even more confidence in our capacity to hit our 2023 to 2025 LRP revenue objectives; that's all I had for my prepared remarks; at this point I'd like to hand the call back to the operator for Q&A.

Shagun Singh Chadha

analyst
#6

Based on our calculations, this acquisition should contribute roughly 50 basis points to Teleflex's total growth, plus 400 basis points to the Interventional Urology segment. Is that roughly correct? Also, does it help counterbalance some of the softness in UroLift? Or does your 8% to 9% LRP remain unchanged?

Liam Kelly

executive
#7

Thanks so much for that question, Shagun. I'll begin with the part about the LRP. When it comes to the LRP, buying Pallet strengthens our confidence that we can at minimum hit the 6% growth outlined in our LRP. Here's how it breaks down. Durable core is set to expand at 5%. Considering how we've done so far this year and what we anticipate for the rest of the year, we're extremely confident about that 5%. The high-growth portfolio is going to expand at a minimum of 12%; and inside that, the Interventional Urology business unit, which is going to encompass Palette, is going to expand at a minimum of 8%. So adding Palette, we believe, secures our capacity to reach that 6% LRP growth we presented at our Capital Markets Day. As for the contribution, what contribution it's going to make to Teleflex's future growth, well, your math is quite accurate. It's bringing in $56 million this year. It's set to expand in the high-teens, to the low-20s in 2024; and I genuinely think that sort of figure ought to be sustainable into 2025 too. So clearly, your math is really right on target; and I think it's a key point to mention, as I stated in my prepared remarks, the gross margins from Palette are a truly significant factor; and to the extent that it's not only accretive to Teleflex; it's accretive to the Interventional Urology business unit right now and is accretive to the high-growth portfolio. Thanks for the question, Shagun.

Shagun Singh Chadha

analyst
#8

And as a quick follow-up regarding UroLift, could you go into more detail about the patterns you're observing? I'm aware that the comparisons for patient volume were somewhat simpler this quarter. But on a basis adjusted for those comps, could you expand on what trends you're noticing?

Liam Kelly

executive
#9

Yes. Throughout the first half of the year, we've continued to observe a decline in the number of patients coming to urologists. I believe during — inside the quarter, there were a few positive signs, I suppose, in that the hospital growth rate kept going; pressure persists on the office side of service, which is still a bit of a difficulty for us; we keep training a substantial number of surgeons. And in fact, we noticed an increase in how many surgeons we trained during Q2, yet the office side of service stays problematic for this product in the quarter, Shagun.

Jayson Bedford

analyst
#10

I'd like to circle back to what was said regarding the Titan Stapler. The guidance reduction there appeared to hinge on VAC committee approvals taking more time; so I'm curious, what exactly is driving that resistance? Is additional clinical evidence required? Could pricing be the problem? I'd really like to explore this a bit further.

Liam Kelly

executive
#11

Sure, Jayson. Clearly, when we first set expectations, the bottom end sat at $30 million. Today it's in the high-teens. Titan should still play a meaningful role in the LRP, in our view. The resistance shows up as we work through the VAC committees, and those committees create a ripple effect that touches proctoring. As I mentioned during my prepared remarks, the count of surgeons we proctored rose twofold between Q1 and Q2, which is a positive sign. The real obstacle, Jayson, is simply the clock. Given how exceptionally well this product performs, we had assumed differently. That's the truly encouraging part. The product delivers precisely what it was designed to deliver. Another key point: this end market is enormous, at $300 million. So after we clear the value analysis committees, adoption follows and things move along nicely. It's merely requiring more time than anticipated; we're at an early stage of the ramp. The market is large; a path forward exists; we understand our next steps; it's simply that reaching the finish line takes longer as we move along that adoption curve; and I'd add that having the buttress material available throughout all of 2024 is going to matter a great deal for us. Strictly speaking, buttress isn't required for our product since it's a full staple line. However, when performing a gastric sleeve, 60% of Bariatric surgeons rely on buttress, and that represents the standard of care. A surgeon will explain it this way: I use buttress because I want to sleep at night. It's simply the standard of care; and I believe having it available in 2024 will help carry us through as well. But the bottom line is time, Jayson. Nothing major is blocking us. Pricing isn't the problem. Neither is product performance. The clinical data we require is already in hand. So we possess everything necessary to succeed, yet these VAC committees are simply taking longer to convene and let us move through the system.

Jayson Bedford

analyst
#12

Alright. Liam, that was really useful. And just a quick follow-up. OEM is still going strong there. Is it fair to say there's nothing that's kind of one-off or stocking baked into that figure, and you remain confident in what ought to be a robust double-digit growth outlook for OEM?

Liam Kelly

executive
#13

Yeah. I'd say OEM has done remarkably well, not only in this year, but across the prior 2 years too, landing just under 20%, which is a stellar result. This is a business where our visibility is really solid. To answer you straight, there aren't any major one-time stocking items. This is purely performance. It's winning share from other competitors in the market. It's also that acquisition we made a number of years back, genuinely helping us move forward, but it's truly strong performance from Greg and the whole team in the OEM division. And I do think OEM will see good, solid double-digit growth this year, and I do think the future looks good for that over the foreseeable future given the visibility we have.

Anthony Petrone

analyst
#14

Liam, let's shift over to Standard Bariatrics for a moment. Could you give us an update on how traction looked this quarter and what you anticipate through year-end for Standard? Obviously, we've all been picking up some chatter about GLP-1s cutting into Bariatric procedures from Intuitive. So an update there would be great, and then I've got a follow-up about earnings.

Liam Kelly

executive
#15

Sure thing, Anthony. During our prepared remarks we mentioned this, and at present our expectation for Standard Bariatrics sits in the high-teens. There is, I'd say, a certain amount of GLP-1 impact; the bigger challenge, though, is working through those VAC committees; and before you can proctor, the VAC committee has to clear you. In my response to Jayson's question, I noted that the count of surgeons we proctored went up twofold between Q2 and Q1. The product is doing extremely well. Bringing in buttress is going to be a boost for us. My view is that GLP-1s do have a bit of an effect, though not a major one. We're simply building up to ramp along this curve. I'd also say opinions differ on GLP-1s, they secure the reimbursements, it covers a briefer stretch of time. So when you speak with the majority of Bariatric Surgeons, their sense is that the effect is near-term. Over the longer horizon, though, they don't anticipate any lasting effect on gastric sleeve surgeries. The weight loss achieved with gastric sleeve is far greater than what GLP-1s deliver; still, we're monitoring this extremely carefully, Anthony, and I appreciate the question.

Anthony Petrone

analyst
#16

And then maybe for Tom, on the margin side and what the trajectory looks like — you moved it to 26% to 26.75%. Could you give us a brief walk-through as we look out through the LRP to '24 and '25: how should we think about building in margin expansion that's in line with, or derived from, whatever is left in the LRP, and how does that translate into earnings power? At this point it gets a bit clouded by the time you get down to the earnings line, because of the Palette acquisition and some moving pieces below the line. So how should we layer this in? Given the guidance we have now through the LRP, how do we frame margin expansion from here? And with additional drivers now on the nonoperating lines, how does that play into earnings power?

Tom Powell

executive
#17

Okay. Well, as we talked about earlier this year, at that point we reaffirmed the LRP guidance. The way I think about adding Palette is that on a full year basis, this product ought to bring in about $56 million of revenue this year. Obviously, we wouldn't have it for the entire year. But over the next couple of years, it should then grow in the high-teens to low-20s. And as we said, we expect it to be margin accretive to the IUBU business units, to all of Teleflex, within the high-growth portfolio. So we see this as fitting in quite well and providing some additional comfort as we look toward future years in our margin progression, including contributing roughly $18 million.

Nathan Treybeck

analyst
#18

This is Nathan Treybeck, sitting in for Larry. Could you talk about Palette—particularly the way it stacks up against where UroLift sits—and how much of the U.S. market has been reached up to this point? Also, as things stand, is Barrigel expanding the overall market or taking a slice of it?

Liam Kelly

executive
#19

Yes, Nathan, and thanks a lot for asking. Our take is that this is an opportunity to grow the market. If we look at the interventional urology customers we have today, only 20% of them are using Barrigel spacing technology at present, even though 97% of those same customers do treat prostate cancer. So from our standpoint, in the domestic United States market, that adds up to a chance to expand the market. The product is approved in EMEA, and it also has approval in Australia. Once it's part of our portfolio, we'll pursue clearances in more regions. That said, we definitely see room for better margins here. We also believe we can put our existing sales team to work and take advantage of that distribution network. Today we have a genuinely worldwide route to reach urologists, and we're confident the market can be expanded. There are other spacing products on the market. With one competitor talking about spacing and another building awareness, we're confident ours beats anything out there right now; you can sculpt it; you can see it; injecting it is simple. It doesn't set too fast. It takes just one step. It can be reversed. Our clinical results have been outstanding. We've had zero embolisms, zero adverse events tied to the device, and strong clinical evidence backing the product. The growth trajectory is something we really like. The margins are something we really like. And the synergies across our sales team are something we really like. We won't factor this into our model, but there's a chance it could create a halo effect for UroLift as well, by opening doors to urologists who in the past might not have been willing to adopt a new technology such as UroLift.

Nathan Treybeck

analyst
#20

All right, and could you share your big-picture views regarding 2024, given this acquisition that's anticipated to dilute by $0.35? For instance, how well can you handle that dilution? I mean, the street's projecting $14.50 in EPS for next year?

Liam Kelly

executive
#21

Yeah. Nathan, on this call we won't dive into 2024. The year is half over. For a second consecutive quarter, we've lifted our revenue guidance; our confidence in the company's position is strong; additionally, we've kept this year's EPS guidance intact despite the $0.15 dilution stemming from Palette. So our feelings about where we stand are quite positive, and once we reach February of next year, we'll address 2024 guidance. Regarding the LRP, I've already shared remarks about our belief and confidence in delivering every element of the revenue profile with Palette inside our LRP 6% and all the pieces of that which I just detailed.

Matthew O'Brien

analyst
#22

Liam, when we discuss Palette briefly, the Barrigel product received approval in May of last year. You're stating it now accounts for at least most of total revenue per Palette. I lack the figures, yet I assume that's $30 million or $40 million in revenue over a year basically that they've already produced. And then you mention roughly high-teens to low-20% growth for next year. I'd imagine that simply if they managed such rapid growth, you folks at Teleflex could achieve a comparable rate. So why is high-teens, low-20% the correct figure? Why not 30%, 40%, 50%? I realize you must integrate it, but why wouldn't it be much higher than that, considering how effectively they performed with it independently?

Liam Kelly

executive
#23

Well, I believe, Matt, all you've said, it's difficult for me to argue too strongly; we will certainly have additional sales reps available. We possess a highly robust sales team across the United States and worldwide for this call point. I mean I think the high-teens low-20s is likely the appropriate figure for us at present. Should it exceed that, it exceeds that and everyone's delighted. I think for us, we currently feel that's the appropriate figure. You're right. We must integrate it; it isn't the most challenging integration globally in complete honesty; it's 1 call point, 1 big large call point. And then clearly, the <<inaudible>>, we have a methodology to handle that via adding clinical trainers. And this is an investment hypothesis for us with adding Palette; we are going to keep expanding this market and growing this market. And if it's superior in the high-teens and low-20s, we'll inform you, and we'll grow it from there. But it's — we feel it's an excellent transaction. And if it's superior to what we anticipate, then the multiple is superior to what we anticipate and everything within that dynamics of it is superior to what we anticipate.

Jayson Bedford

analyst
#24

Understood. That makes sense, and I appreciate the answer. Moving back to UroLift — I realize it's becoming a smaller piece of the total business, but other med tech areas still haven't bounced back from the pandemic. Women's health comes to mind as one example. Is this a category where, particularly in outpatient and physician office settings, things are now probably structurally different, and it most likely won't reaccelerate? So the 8% to 9% you mentioned last quarter — is that probably not going to happen going forward?

Liam Kelly

executive
#25

Yeah. To be fully transparent, at the start of the year I believed UroLift would bounce back. My expectation was growth of roughly 3%; now, looking ahead to the full year, I'd expect Interventional Urology, which would include Palette, to see a low single-digit decline, around 3% as things stand. What I think has shifted: the market is enormous. This condition is progressive. There are plenty of men out there suffering from BPH. The pressure in the office, Matt, the way I see it today, is the actual problem. If you look back to '17, '18, '19, we expanded the market by using the office call point to draw men in from the drug dropout and the drug category, and during that stretch we could convert those men; with reimbursement changes, patient flow issues, and staffing shortages, that channel is for the time being struggling to bring those men in and grow the market. So I believe we need to fix the office channel. And honestly, I just can't see that being fixed over the next 2 quarters. So I think recovery is going to take some time. That said, this quarter we trained more docs than in the prior quarter for a number of quarters. So docs are raising their hands to get trained. The international profile is excellent. I couldn't be happier with what's happening overseas. And domestically, for the rest of the year, I think it's going to do what I said it's going to do. There are a couple of green shoots. It was minus 5%. Last year, it was minus 5% in the first quarter; it was minus 2.5% this quarter; so there are a couple of green shoots here, some positivity there. But I think that office call point is challenged right now with all of the factors that are playing into it.

Craig Bijou

analyst
#26

I'd like to kick things off by digging into a few pieces of the LRP. Specifically, Liam, my understanding is that you're now projecting Interventional Urology, Pallet included, to expand by no less than 8%, and that would imply the underlying UroLift growth rate over the longer term comes down a notch. I just want to confirm that's right. And perhaps what's behind it — it sounds like the U.S. is the driver, but could you give us a bit more detail on how you see UroLift playing out across the coming years? Then there's Standard Bariatrics. I realize you're anticipating fairly solid expansion there over the next few years. I'd just like to get a sense of how we ought to frame that growth rate in '24 and '25 compared with your prior expectations.

Liam Kelly

executive
#27

Yes. Let me take the first portion of what you asked. Your assumption and the way you worked the math — I can't argue with it, you've got it exactly right; and that's precisely why I have such confidence in the 6% LRP. At this point within the LRP, I'm not counting on anything here, nor am I counting on anything coming from UroLift. The international market is performing well. Should the domestic market bounce back, that's a positive for investors, a positive for Teleflex, and a positive for our LRP. The margin profile is solid; so essentially, the way I see it, this more or less removes UroLift from the equation when it comes to the LRP. As for Standard Bariatrics, as I mentioned before, the market is enormous. Once we've cleared the VAC committees and gotten the surgeons proctored. What we're aiming for here is to keep delivering on the product's performance so we can keep capturing our deserved share within the bariatric sleeve market. The bariatric sleeve market won't disappear on account of GLP-1s; it will exist indefinitely. There's a role for this. Ask any surgeons and they'll confirm that. So I genuinely believe it will be a significant contributor to the LRP in our '24 and '25 as we expand into that enormous market.

Craig Bijou

analyst
#28

Understood. As a quick follow-up regarding '24, I realize you won't be offering guidance or discussing what the Street has projected; still, I'd appreciate hearing about any factors that will influence '24. Clearly, there's the Palette acquisition, plus the MSA sunsetting. So I'd like to ask you directly about what we ought to consider regarding '24 EPS, and whether perhaps the messaging you've provided before isn't entirely captured in the Street's numbers?

Liam Kelly

executive
#29

I'll have Tom address the EPS. I believe you've identified the 2 primary items the Street must consider. Clearly, the MSA — that $70 million in revenue disappearing next year — then you add in, and that carries very low margins and affects EPS by roughly $0.25. Then you factor in the Palette acquisition, which naturally brings back $56 million in revenue for the base year and, of course, subsequently expands at a rate from high-teens to low-20s. So those represent the positive and negative elements on the top line. I don't expect Tom to delve into specific details regarding 2024 EPS, but I think those are the 2 key items, Tom, correct?

Tom Powell

executive
#30

They do. A few other items are on our radar too, I'd add. Recently our FX rates have improved quite nicely, so next year that ought to deliver a half-year gain; on top of that, we're beginning to notice some easing on the inflation front. For instance, sea freight costs have already retreated, and delivery timelines are getting much faster, which opens the door to several actions, among them reducing how much inventory we hold, and that will clearly benefit cash flows as we keep bringing those balances down. Still, I'd say the main shifts center on the MSA, Palette, and then the — FX and inflation are things we're monitoring carefully, though they might end up acting as tailwinds for us.

Kristen Stewart

analyst
#31

Tom, just on the bottom line, why reaffirm the guidance instead of narrowing the range?

Tom Powell

executive
#32

That's a reasonable question. When we consider how things have played out, we examined every positive and negative factor from the quarter, along with year-end considerations. So if you look at what we've discussed, the EPS range was essentially shaped by incorporating the additional dilution of $0.15 from Palette. Then, tied to the recalls in the second quarter, we incurred a further $0.15 in expense. As I noted, FX has gotten better. Because of the expected benefit for both the second quarter and the full year, that gives us an offset of $0.15. The remaining piece is a mix of stronger operating performance in the second quarter and the second half. So basically, several adjustments since our prior guidance largely cancel each other out. As Liam said, we're absorbing the dilution from the Palette acquisition while keeping guidance intact. So in that sense, we're effectively raising it, so to speak, because we're now covering something new. But as we keep watching the year, we'll assess it and revisit the range in the third quarter.

Richard Newitter

analyst
#33

This is Ling here, sitting in for Rich. I was hoping you might be able to give us a bit of detail on how things are trending in that high-growth portfolio of yours — things such as MANTA thermostatic devices, and so on?

Liam Kelly

executive
#34

Sure. Like I mentioned during my prepared remarks, MANTA keeps making further inroads into the market and is set to deliver genuinely strong double-digit growth. When you turn to the remaining parts of that high-growth portfolio, 2 of them have already come up in our discussion. And our expectation is that UroLift, within the high-growth portfolio, will land comfortably inside that high single-digit growth. If you'll allow me, I'd like to spend a moment on the durable core. My view is that the durable core has been turning in a really, really strong performance. OEM gave us excellent results, which came up earlier, while Interventional Access has performed greatly, and so has Asia Pacific. Those investors who know Teleflex well will know that both Interventional and APAC deliver very strong gross margins for the company. So the entire Teleflex portfolio, in our view, is functioning really, really well. That goes from the durable core through to the high-growth. And our belief is that for 2 quarters in a row, we raised our revenue forecast 2 quarters in a row. And compared with last year, we have witnessed meaningful improvement. Thinking back to last year, our growth was 4.3%. If you look at our guidance for this year, the midpoint comes in at almost 5.9%. So meaningful improvement is what we've seen. And once more, that's the benefit of being a diversified global company. Not every single thing will turn out the way you expect. But once you put it all together, it all adds up. And it's — in my view it's a solid performance, and bringing Palette in is really going to help us.

Analyst

analyst
#35

Excellent, that's helpful. Perhaps I could ask a second question about margins. Would you take us through how gross margin and operating margin are expected to trend over the course of the year?

Liam Kelly

executive
#36

You're asking how gross margin and operating margin will move across this year?

Analyst

analyst
#37

Right.

Liam Kelly

executive
#38

Let me get Tom to take that one.

Tom Powell

executive
#39

Yes, certainly. So, the first thing to grasp, I'd say, is that currency movements really matter a lot when it comes to how margins end up. In Q1, foreign exchange actually gave us a significant boost. By Q2, that flipped to a slight drag on gross margin; and looking ahead to Q3 and Q4, once the FX effect hits — or rather, we anticipate the FX effect on gross margins will be even larger. So, setting aside the currency effect, you'd observe gross margin getting better quarter after quarter across the year, with a pretty substantial gain between Q1 and Q2 and then once more between Q3 and Q4. If you leave FX in the picture, what you'll find is gross margin staying roughly flat each quarter, somewhat weaker in Q3, somewhat better in Q4, similar to what we just saw in Q2. During Q2, we had some pluses and minuses. Clearly, there was the recall expense. Currency, as I said, was a modest drag, but we also benefited from good pricing and certain credits from overseas markets. So on balance, I'd say keep an eye on how currency movements shake out. And if you set that aside, you'd find gross margin improving sequentially; and operating margin follows a very similar pattern. Remove the FX effect, and you'd find op margin improving quarter over quarter across the year. Of course, we can't ignore FX. Consequently, what you'll find is gross margin coming in slightly weaker in Q3 and either flat or slightly better in Q4 compared with what we saw in Q2.

George Sellers

analyst
#40

Let me pivot back to Palette for a second. Among the 97% of UroLift users who are also being treated for prostate cancer — and I think you mentioned that 20% have already been using Barrigel — are those patients already on some kind of spacer or product too? Or does this look more like an untapped opportunity?

Liam Kelly

executive
#41

George, that's a great question. There would be a white space opportunity of roughly 60%. Adding it up, about 40% of them are on some type of spacing product, with 20% of them on Barrigel. That leaves you at approximately 60% white space. And once more, I'll repeat: for us, this isn't about going after the other 20%; it's about going after the 60%, teaching the physicians about the advantages of using spacing, the advantages of Barrigel as a spacer — the ones I already listed — and eliminating that toxicity from other organs surrounding the prostate. So it's really about white space, George, growing within an existing customer, the urology oncologists, which is a great call point for us to reach where some of the product is used by those individuals. So I'm really encouraged by that, and I think it's a nice opportunity.

George Sellers

analyst
#42

All right. That is genuinely useful. Moving over to the OEM segment, it keeps delivering outstanding results; and it sounds like you can see that carrying on through the rest of the year; but might you share a bit more on the factors behind that strong performance? And what should we assume about how durable that is across the LRP?

Liam Kelly

executive
#43

Yes. I'd say excellent question once more, George. I'd say what makes the OEM businesses so attractive is that this holds true across the Board. We have very robust double digit growth in the catheter business. We have very robust double digit growth in the suture business; we have very robust double-digit growth in the completed product business. And clearly, the complex catheters among those catheters are doing remarkably well. It spans the entire Board. You're right. We enjoy excellent visibility into this business. This is one business where customers place orders far in advance to ensure they have capacity reserved. And once more, I believe we have — we're truly heartened by what we're seeing. It does dilute our gross margins. But wow, does it boost our op margins? This is a fantastic business for us and one that's doing remarkably well with long visibility; and if I could locate another tuck-in to add to OEM, we have the capital on hand, I'd do it in the morning since it's — we have solid growth in there and a very strong customer base.

Larry Keusch

executive
#44

Appreciate that, Jayal, and thanks as well to all of you who took the time to be with us on today's call. That brings the Teleflex Incorporated Second Quarter 2023 Earnings Conference Call to a close.

Operator

operator
#45

You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.